Stempeutics Research has signed an out-licensing deal with Cipla for novel stem cell product ‘Stempeucel-DFU’ for treating non-healing diabetic foot ulcer. The deal consists of upfront payment and various milestones-based payments.
Under the agreement, Cipla will get exclusive marketing rights for five years in India for the diabetic foot ulcer (DFU) product. Stempeutics will manufacture and supply the product to Indian company.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.
